Bausch’s Salix Pharmaceuticals has initiated a lawsuit against Alvogen’s Norwich Pharmaceuticals unit, alleging that its planned generic version of Xifaxan infringes on a series of patents. The legal action, filed in a New Jersey federal court, targets the generic alternative to Xifaxan, a medication widely used for treating diarrhea and certain brain disorders. This development follows a recent favorable decision for Bausch at the Federal Circuit, further intensifying the ongoing patent disputes between the two companies.
For more details, visit the original article.